• Aurinia Pharmaceuticals Inc AUPH.OQ AUPH.O is expected to show a rise in quarterly revenue when it reports results on October 31 (estimated) for the period ending September 30 2024

• The Victoria British Columbia-based company is expected to report a 5.8% increase in revenue to $57.693 million from $54.52 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Aurinia Pharmaceuticals Inc is for earnings of 2 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is 10.00​, above​ its last closing price of $7.24. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated October 29 at 13:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)